The outbreak nobody wanted back
Measles is doing that annoying thing where it reminds everyone why vaccines exist. Two unvaccinated Lancaster County residents died in Pennsylvania, marking the state’s first measles fatalities in 35 years and the first U.S. deaths from the disease this year.
The bigger macro-ish nugget? Cases are still piling up. The CDC has logged 2,777 confirmed cases through Aug. 20, and prediction markets are basically saying, “Yeah, this thing keeps spreading.” Polymarket gives an 87% chance the U.S. hits 4,000 cases this year.
Why investors are even reading about this
This is not some sneaky earnings supercycle. But it does matter a little for vaccine makers like Merck and GSK, which together make the FDA-licensed measles-containing combination vaccines sold in the U.S.
- Merck sells M-M-R II and ProQuad
- GSK sells Priorix
- More outbreaks can nudge vaccine awareness and demand higher
That said, this is more of a modest tailwind than a needle-mover. Think “extra foot traffic,” not “new product category.”
Politics enters the chat, because of course it does
The article also notes the White House has been muddying the waters, with President Trump calling the combined MMR vaccine “quite lethal” while Merck and GSK pushed back hard. CMS Administrator Dr. Mehmet Oz later contradicted that claim, saying the MMR vaccine is not lethal.
So now you’ve got public health, prediction markets, and politics all in one stew. A very normal Tuesday, apparently.
Big picture: the outbreak is a reminder that infectious disease headlines can ripple into vaccine demand, but for MRK and GSK this looks more like a small sentiment tailwind than a major fundamental event.